Fierce Health Technology January 13, 2020
CVS Health is taking a multipronged approach to addressing the costs associated with gene therapies.
As more gene therapies are set to come down the pipeline, payers and employers can proactively prepare for those products in several different ways, according to a new white paper from CVS Health.
In the report (PDF), the healthcare giant offers a four-point strategy health plans and plan sponsors can adopt to get out ahead of the costs associated with these treatments, which are set to balloon significantly as they’re applied to more common diseases.
The suggested steps are:
Extend the centers of excellence approach to gene therapy providers.
Continue to evolve the role...
Today's Sponsors
Today's Sponsor